Stem Cells, Cellular Therapeutics and Regenerative Medicine - The Online Scientific Community

Thermo Fisher Scientific to Offer BellBrook Labs’ iuvo Microconduit Array Products
Tuesday, February 14, 2012
Exclusive distribution agreement gives cell biologists broader access to advanced tools for oncology, stem-cell and inflammation research.

Georgia Tech Develops Computational Algorithm
Tuesday, February 14, 2012
High-throughput DNA sequencing technologies are leading to a revolution in how clinicians diagnose and treat cancer. The molecular profiles of individual tumors are beginning to be used in the design of chemotherapeutic programs optimized for the treatment of individual patients.

Titian to Provide Roche with Mosaic™ Software for Managing its Global Sample Banks
Monday, February 13, 2012
Ordering, management and workflow efficiency to be optimized using industry-favored software solution.

Broad Microbial Contamination Detection on one platform with results within 8 hours.
Friday, February 10, 2012
The Abbott PLEX-ID system is the only high-throughput technology that offers rapid, broad identification of known or unknown emerging organisms direct from sample, without the need for culture, enrichment or staining.

Roche’s xCELLigence Cardio Instrument Used to Detect Compound Effects on Beating Frequency of Cardiomyocytes
Friday, February 10, 2012
Scientists at the University Medical Center Utrecht and Bioscience Department of AstraZeneca R&D have tested Roche’s xCELLigence Cardio Instrument.

Mesenchymal Stem Cells Have New Cell Culture Environment
Wednesday, February 08, 2012
BD Mosaic(TM) mesenchymal stem cell serum-free cell culture environment increases cell expansion while decreasing culture time.

<<	5 6 7 8 9 10 11	>>
Showing Results 71 - 80 of 398

Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.

FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.

Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.

Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.